Johnson & Johnson(JNJ) - Stock detail

Johnson & Johnson

US
JNJ
Johnson & Johnson(Listing date: 09/25/1944)

Johnson & Johnson was incorporated in New Jersey in 1887. Johnson & Johnson and its subsidiaries are engaged in the research and development, manufacturing and sale of various products in the healthcare field. Johnson & Johnson is a holding company, with its operating companies located in nearly all countries around the world. The company's primary focus is on products related to human health and well-being. The company is divided into two business segments: Innovative Medicine and MedTech.

🎯 Johnson & Johnson (JNJ) 💰 Analysis Report 📅 Generated: 2026-06-03 17:44:40 ET

Investment Analysis: Johnson & Johnson (JNJ)

Investment Recommendation: SELL / REDUCE EXPOSURE

Target Price: $215.00 (US Dollar)

Confidence Level: 0.75

Risk Score: 0.65 (Moderate-High Risk)


Detailed Reasoning

1. Synthesis of Analysis Reports

My recommendation is based on a synthesis of all provided data, with the technical and market structure arguments proving most compelling for the near-term outlook.

Technical Analysis (Overwhelmingly Bearish):

  • Confirmed Downtrend: Price ($223.24) trades below all key moving averages (5-day: $225.15, 20-day: $227.18, 60-day: $233.07) in a classic “death cross” pattern.
  • Severe Selling Pressure: Money Flow Index (MFI) at 0.37 indicates catastrophic net outflows. High-volume down days (e.g., 13.72M shares on May 29) show institutional distribution.
  • Critical Market Structure: Estimated chip distribution shows 76% of holders are underwater with average cost of $228.21. This creates massive overhead supply resistance at $228-$230, where trapped sellers will likely exit at breakeven.
  • Oversold but Not Reversing: While short-term indicators (RSI_6: 31.05, Williams %R: -83.63) suggest oversold conditions, in a strong downtrend these often precede further decline rather than reversal.

Fundamental Analysis (Mixed but Cautious):

  • Valuation Not Compelling: Forward P/E of 20.43 and P/S of 24.55 are premium multiples for a company whose recent news narrative focuses on dividend stability rather than growth acceleration.
  • Anomalous Margins: The Q1 2025 net margin of 50.24% is unsustainable (per the report itself). Using normalized metrics, the stock may be fairly valued rather than deeply undervalued.
  • Financial Health: Moderate leverage (Debt/Assets: 59.67%) in a rising rate environment warrants caution.

Market Sentiment & News (Neutral to Negative):

  • Dominant theme is “Dividend King” status, but news questions if the 48% one-year surge led to overvaluation.
  • Short-term sentiment is neutral-to-slightly negative with expected price movement of -2% to +1%.
  • No immediate, company-specific bullish catalysts in the news flow.

2. Target Price Justification: $215.00

The $215 target is derived from multiple converging factors:

  1. Technical Support Levels:

    • Immediate support at $219.16 (lower Bollinger Band)
    • Next significant support zone extrapolated from trend analysis at $215-$218
    • A break below $219 likely triggers stop-losses and accelerates decline toward $215
  2. Fundamental Trading Range:

    • The fundamentals report suggests a near-term trading range of $215-$245
    • Current price near range top suggests higher probability of testing range bottom
  3. Risk-Reward Assessment:

    • Upside limited to $228-$230 (overhead resistance from trapped sellers)
    • Downside risk to $215 represents ~3.7% decline from current price
    • Unfavorable risk-reward ratio for new long positions
  4. Market Context:

    • “Higher for longer” interest rates pressure valuation multiples of slow-growth stocks
    • Sector rotation away from defensive names in current market environment

3. Action Plan

For Existing Holders:

  1. Use any oversold bounce toward $228-$230 to reduce exposure
  2. Implement stop-loss at $219 (just below Bollinger Band lower limit)
  3. Consider tax implications of selling if in taxable account

For Potential Buyers:

  1. Avoid new long positions until confirmed reversal signal
  2. Reversal confirmation requires:
    • Strong volume-backed close above 20-day EMA (~$227.66)
    • Break above 60-day MA ($233.07) with conviction
  3. More attractive entry likely available at $215 or lower

4. Key Risks to Monitor

  1. False Breakdown Risk: If $219 support holds and stock rallies above $230 with volume, bearish thesis weakens
  2. Dividend Support: 3%+ yield may attract income buyers at lower prices, providing unexpected support
  3. Unexpected Catalyst: Positive pipeline news or favorable legal settlement could reverse sentiment
  4. Broader Market Rally: Strong overall market could lift all stocks, including JNJ

Time Horizon: This analysis applies to a 1-3 month investment horizon. For long-term (5+ years) dividend investors, current prices may be acceptable for dollar-cost averaging, but near-term technical damage suggests better entry points will likely emerge.

Final Note: While Johnson & Johnson remains a high-quality company with excellent long-term fundamentals, the current technical setup and market structure create an unfavorable near-term risk profile. The prudent action is to reduce exposure and wait for either a better price or clearer signs of trend reversal. ✅ Analysis Complete